

AC/WDR:gh - 09/17/07 764558 E-083-2002/2-US-02

Attorney Ref. No. 4259-64104-02

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled USE OF DISCOIDIN DOMAIN RECEPTOR 1 (DDR1) AND AGENTS THAT AFFECT THE DDR1/COLLAGEN PATHWAY, the specification of which

- ☒ was filed on September 9, 2004 as United States Application No. 10/507,385; and
- ☒ was described and claimed in PCT International Application No. PCT/US02/39793, filed on December 11, 2002.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. If this is a continuation-in-part application filed under the conditions specified in 35 U.S.C. § 120 which discloses and claims subject matter in addition to that disclosed in the prior copending application, I further acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of an PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)	Country	Filing Date	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date
60/363,734	March 12, 2002
60/380,978	May 15, 2002
60/419,179	October 16, 2002

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(e) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of

AC/WDN:gm 09/17/07 764558 E-083-2002/2-US-02

Attorney Ref No. 4239-64104-02

Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

Application No.	Filing Date	Status: patented, pending, abandoned

Address all telephone calls to Anne Carlson, Ph.D., telephone number (503) 595-5300 and facsimile number (503) 595-5301.

Address all correspondence to **Customer Number 36218:**

KLARQUIST SPARKMAN, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, OR 97204-2988

The undersigned acknowledges that the practitioners associated with Customer Number 36218 accept and follow instructions from the Office of Technology Transfer at the National Institutes of Health, and not the undersigned inventors.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of First Inventor:	Teizo Yoshimura	
Residence:	5709 Etzler Road Frederick, Maryland 21702	
Mailing Address:	NIH/NCI-Frederick Building 559, Room 9 Frederick, Maryland 21702	
Citizenship:	Japan	
Inventor's Signature	_____	Date _____

Name of Second Inventor:	Hidenobu Kamohara	
Residence:	6-6-7 Tsuboi Kumamoto Kumamoto 860-0863 Japan	
Mailing Address:	Department of Gastroenterological Surgery Graduate School of Medical Sciences Kumamoto University 1-1-1 Honjo, Kumamoto Kumamoto 860-8556 Japan	
Citizenship:	Japan	
Inventor's Signature	<i>Hidenobu Kamohara</i>	Date <i>September 18 2007</i>

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled USE OF DISCOIDIN DOMAIN RECEPTOR 1 (DDR1) AND AGENTS THAT AFFECT THE DDR1/COLLAGEN PATHWAY, the specification of which

- ☒ was filed on September 9, 2004 as United States Application No. 10/507,385; and
- ☒ was described and claimed in PCT International Application No. PCT/US02/39793, filed on December 11, 2002.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56. If this is a continuation-in-part application filed under the conditions specified in 35 U.S.C. § 120 which discloses and claims subject matter in addition to that disclosed in the prior copending application, I further acknowledge the duty to disclose material information as defined in 37 CFR § 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of an PCT International application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)	Country	Filing Date	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date
60/363,734	March 12, 2002
60/380,978	May 15, 2002
60/419,179	October 16, 2002

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of

Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT International filing date of this application:

Application No.	Filing Date	Status: patented, pending, abandoned


Address all telephone calls to Anne Carlson, Ph.D., telephone number (503) 595-5300 and facsimile number (503) 595-5301.

Address all correspondence to **Customer Number 36218:**

KLARQUIST SPARKMAN, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, OR 97204-2988

The undersigned acknowledges that the practitioners associated with Customer Number 36218 accept and follow instructions from the Office of Technology Transfer at the National Institutes of Health, and not the undersigned inventors.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of First Inventor:	Teizo Yoshimura		
Residence:	5709 Eitzer Road	8919 Mountainberry Circle	TR, 7/18/2007
	Frederick, Maryland 21702		
Mailing Address:	NIH/NCI-Frederick		
	Building 559, Room 9	Building 560, Room 31-36	TR, 9/10/2007
	Frederick, Maryland 21702		
Citizenship:	Japan		
Inventor's Signature			Date 9/10/2007

Name of Second Inventor:	Hidenobu Kamohara		
Residence:	6-6-7 Tsuboi		
	Kumamoto		
	Kumamoto 860-0863		
	Japan		
Mailing Address:	Department of Gastroenterological Surgery		
	Graduate School of Medical Sciences		
	Kumamoto University		
	1-1-1 Honjo, Kumamoto		
	Kumamoto 860-8556		
	Japan		
Citizenship:	Japan		
Inventor's Signature	_____		Date _____